Kazia Therapeutics Files January 2025 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Jan 30, 2025 · CIK: 1075880
Sentiment: neutral
Topics: sec-filing, routine-report, foreign-private-issuer
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed its monthly 6-K report on Jan 30, 2025. Standard update.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on January 30, 2025, reporting for the month of January 2025. The company, previously known as Novogen Ltd, is based in Sydney, NSW, Australia, and operates in the Pharmaceutical Preparations sector. This filing is a routine report for a foreign private issuer.
Why It Matters
This filing provides routine updates for investors and regulators regarding Kazia Therapeutics' ongoing operations as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific material events or financial disclosures that would indicate a change in risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- January 2025 (date) — Reporting period
- January 30, 2025 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was previously known as Novogen Ltd, with a date of name change on December 28, 1998.
What is Kazia Therapeutics Limited's primary business sector?
Kazia Therapeutics Limited operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office of Kazia Therapeutics Limited is located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file an annual report on Form 20-F?
Yes, Kazia Therapeutics Limited indicates that it files or will file annual reports under cover of Form 20-F.
Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2025-01-30 07:57:59
Filing Documents
- d907461d6k.htm (6-K) — 10KB
- d907461dex991.htm (EX-99.1) — 11KB
- 0001193125-25-016272.txt ( ) — 22KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On January 30, 2025, Kazia Therapeutics Limited (the Company) issued a press release titled Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the respective quotes of Dr. John Friend, Chief Executive Officer of the Company, and Sudha Rao, Professor at QIMR Berghofer, contained in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-276091 and 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated January 30, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 30 January 2025